Jul 2026· Journal of Immunology· Vol 215· 0 citations
TL;DR
It is shown that aAPCs can drive differentiation of CD4 CTL in vitro and are tunable by cytokine concentration and milieu, particle size, and antigen specificity, which lays the groundwork for further investigation of this non-canonical T-cell subset.
Abstract
T-cell-based immunotherapies like ACT have mostly focused on CD8 T cells, but cytotoxic CD4 T cells (CD4 CTLs) are increasingly recognized as contributors to anti-tumor immunity. As such, we created a CD4 T-cell activating nanoparticle platform, termed the artificial antigen presenting cell (aAPC). Under Th1-skewing conditions, aAPC-stimulated CD4 T cells upregulate granzyme B and mediate cell lysis. We hypothesize that aAPCs can provide a tunable system to probe how environmental cues influence CD4 T-cell cytotoxicity.
aAPCs are formed by covalently conjugating signal 1 to amine-coated iron-oxide nanoparticles. CD4 T-cells from transgenic OT-II mice were isolated from organs and cultured in vitro with aAPCs and soluble signals 2 and 3 for 7 days. Cells were expanded in the presence of CD4 subset-polarizing mixes (Th1, Th2, or Treg), using aAPCs of varying diameters (70 to 4000 nm), or with aAPCs presenting different signal 1 molecules (I-ab OVA or anti-CD3). CD4 CTL and CD4 phenotypic markers (CD44, CD62L, and granzyme B) were assessed with flow cytometry.
aAPCs were used to activate OT-II CD4 T cells in vitro. Th1-skewing conditions promoted expression of cytotoxic-associated transcription factors. Th2- and Treg-skewing conditions failed to induce granzyme B. Smaller aAPCs (70 and 250 nm) supported greater cytotoxic function than larger particles (4 um). Antigen-specific stimulation elicited stronger cytotoxicity than non-specific stimulation. Higher IL-2 concentrations increased both frequency and expression of granzyme B, and favored an effector over memory phenotype.
We have shown that aAPCs can drive differentiation of CD4 CTL in vitro. Furthermore, we show that CD4 CTL phenotype and function are tunable by cytokine concentration and milieu, particle size, and antigen specificity. These findings lay the groundwork for further investigation of this non-canonical T-cell subset, with the ultimate goal of improving the efficacy of T-cell-based cancer immunotherapies.
NIH
Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
Cytotoxic CD4
+
T cells (CD4
+
CTLs) have been identified as a specialized effector population characterized by potent cytotoxic machinery, including granzymes, perforin, and the Fas/FasL pathway, that enables the direct killing of MHC-II-expressing target cells. In addition to their classical helper function,...
Hao-Yang Yu, Jia-Xin Liang, Qi-Xuan Gu et al.· Cellular & Molecular Bio...· 0 citations
Currently, no immunotherapy is approved for T cell acute lymphoblastic leukemia (T‑ALL). High initial response rates to CD7‑directed chimeric antigen receptor (CAR) T cells are limited by profound T cell aplasia and CD7‑negative immune escape, underscoring the need for alternative targets. Here, we show that CD28 is ov...
CD4+ cytotoxic T lymphocytes (CD4-CTLs) are understudied immune mediators with ambiguous origins. Despite expressing RUNX3, granzyme B (GZMB), and perforin (PRF1), CD4-CTLs are frequently classified as Th1 extensions due to shared interferon-γ (IFNγ) and T-BET expression. Here, we identify interleukin-27 (IL-27) as a i...
M. Matias, R. Marrocco, Kyle Magro et al.· bioRxiv· 0 citations
Classically, B and T cells are differentiated by their mutually exclusive expression of surface markers such as CD3 and CD20, but it is now established that a few percent of T cells in human blood display also CD20. We analyzed CD3+CD20+ cells in detail by combining single-cell proteogenomics, FACS, and ImageStream. Th...
Selia Baier, Zhong-Yi Wang, N. Loll et al.· Proceedings of the National...· 0 citations
Successful cellular immunotherapy for cancer utilising cytotoxic T lymphocytes (CTL) requires efficient expansion while maintaining effector function. Understanding how CTL expansion and function are regulated during the cell preparation process is thus important. Here, we show that T cell-specific deletion of Prmt7 us...
Nivine Srour, Kai-Xiu Luo, D. Allard et al.· Nature Communications· 0 citations
Abstract Background Targeting the high-affinity interleukin-2 receptor (IL-2R) on CD8+ T effector cells elicits potent antitumor responses that are augmented when co-administered with programmed cell death protein 1 (PD-1) blockade. Methods Using the mouse IL-2/CD25 fusion protein (mIL-2/CD25) at a high dose (HD) and a...
Kathryn M. Laporte, Janika Põder, D. Ivanova et al.· Journal for ImmunoTherapy of...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.